KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Pacira BioSciences (PCRX) Long-Term Debt Repayments (2016 - 2025)

Pacira BioSciences has reported Long-Term Debt Repayments over the past 9 years, most recently at $202.5 million for Q3 2025.

  • For Q3 2025, Long-Term Debt Repayments rose 211.04% year-over-year to $202.5 million; the TTM value through Dec 2025 reached $20.1 million, up 111.04%, while the annual FY2025 figure was $202.5 million, 2243.33% up from the prior year.
  • Long-Term Debt Repayments for Q3 2025 was $202.5 million at Pacira BioSciences, up from -$182.4 million in the prior quarter.
  • Over five years, Long-Term Debt Repayments peaked at $202.5 million in Q3 2025 and troughed at -$182.4 million in Q3 2024.
  • A 3-year average of $42.5 million and a median of $35.6 million in 2022 define the central range for Long-Term Debt Repayments.
  • On a YoY basis, Long-Term Debt Repayments climbed as much as 211.04% in 2025 and fell as far as 211.04% in 2025.
  • Year by year, Long-Term Debt Repayments stood at $35.6 million in 2022, then crashed by 611.52% to -$182.4 million in 2024, then surged by 211.04% to $202.5 million in 2025.
  • Business Quant data shows Long-Term Debt Repayments for PCRX at $202.5 million in Q3 2025, -$182.4 million in Q3 2024, and $35.6 million in Q4 2022.